SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    ) Brescia , R. J. , Dubin , N. and Demopoulos , R. I. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival . Int. J. Gynecol. Pathol. , 6 , 287293 ( 1987 ).
  • 2
    ) Jenison , E. L. , Montag , A. G. , Griffiths , C. T. , Welch , W. R. , Lavin , P. T. , Greer , J. and Knapp , R. C. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma . Gynecol. Oncol. , 32 , 6571 ( 1989 ).
  • 3
    ) Kita , T. , Kikuchi , Y. , Kudoh , K. , Takano , M. , Goto , T. , Hirata , J. , Tode , T. and Nagata , I. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary . Oncol. Rep. , 7 , 327331 ( 2000 ).
  • 4
    ) Komiyama , S. , Aoki , D. , Tominaga , E. , Susumu , N. , Udagawa , Y. and Nozawa , S. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation . Gynecol. Oncol. , 72 , 342346 ( 1999 ).
  • 5
    ) Fujimura , M. , Yamakawa , Y. , Hidaka , T. , Kataoka , K. , Akada , S. , Teranishi , A. and Saito , S. Absence of estrogen receptor-α expression in human ovarian clear cell adenocarcinoma compared with ovarian serous and endometrioid adenocarcinoma . Am. J. Surg. Pathol. , 25 , 667672 ( 2001 ).
  • 6
    ) Cutolo , M. , Sulli , A. , Seriolo , B. , Accardo , S. and Massy , A. T. Estrogens, the immune response and autoimmunity . Clin. Exp. Rheumatol. , 13 , 217226 ( 1995 ).
  • 7
    ) Bouras , T. , Southey , M. C. and Venter , D. J. Over-expression of the steroid receptor coactivator AIB1 in breast cancer correlates with absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu . Cancer Res. , 61 , 903907 ( 2001 ).
  • 8
    ) King , C. R. , Kraus , M. H. and Aaronson , S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma . Science , 229 , 974976 ( 1985 ).
  • 9
    ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H. HER2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138143 ( 1999 ).
  • 10
    ) Kim , Y. C. , Park , K. O. , Kern , J. A. , Park , C. S. , Lim , S. C. , Jang , A. S. and Yang , J. B. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients . Lung Cancer , 22 , 181190 ( 1998 ).
  • 11
    ) Sato , K. , Moriyama , M. , Mori , S. , Saito , M. , Watanuki , T. , Terada , K. , Okuhara , E. , Akiyama , T. , Toyoshima , K. and Yamamoto , T. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma . Cancer , 70 , 24932499 ( 1992 ).
  • 12
    ) Press , M. F. , Pike , M. C. , Hung , G. , Zhou , J. Y. , Ma , Y. , George , J. , Dietz-Band , J. , James , W. , Slamon , D. J. and Batsakis , J. G. Amplification and overexpression of HER2/neu in carcinoma of the salivary gland: correlation with poor prognosis . Cancer Res. , 54 , 56755682 ( 1994 ).
  • 13
    ) Lei , S. , Appert , H. E. , Nakata , B. , Domenico , D. R. , Kim , K. and Howard , J. M. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival . Int. J. Pancreatol. , 17 , 1521 ( 1995 ).
  • 14
    ) Slamon , D. J. , Leyland-Jones , B. , Shak , S. , Fuchs , H. , Paton , V. , Bajamonde , A. , Fleming , T. , Eiermann , W. , Wolter , J. , Pegram , M. , Baselga , J. and Norton , L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N. Engl. J. Med. , 344 , 783792 ( 2001 ).
  • 15
    ) Fornier , M. , Esteva , F. J. and Seidman , A. D. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer . Semin. Oncol. , 27 , 3845 ( 2000 ).
  • 16
    ) Sasa , H. , Ishii , K. , Hirata , J. , Kikuchi , Y. , Nagata , I. , Kawai , T. , Senoo , A. , Sugita , M. , Sugishita , T. and Tenjin , Y. Establishment and characterization of a CA-125-producing human ovarian clear cell carcinoma cell line . Hum. Cell , 6 , 279286 ( 1993 ).
  • 17
    ) Kiguchi , K. , Iwamori , M. , Mochizuki , Y. , Kishikawa , T. , Tsukazaki , K. , Saga , M. , Amemiya , A. and Nozawa , S. Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Lex-determinant in the dissemination potential . Jpn. J. Cancer Res. , 89 , 923932 ( 1998 ).
  • 18
    ) Nishida , M. and Iwasaki , H. Establishment of a human ovarian clear-cell carcinoma cell line (HAC-2 cell) in vitro . Hum. Cell , 1 , 345346 ( 1988 ).
  • 19
    ) Fujimura , M. , Kataoka , K. , Hidaka , T. and Saito , S. Effect of anti-cancer agents in ovarian clear cell adenocarcinoma . Oncol. Chemother. , 16 , 241244 ( 2000 ) (in Japanese) .
  • 20
    ) Hatanaka , Y. , Hashizume , K. , Kamihara , Y. , Itoh , H. , Tsuda , H. , Osamura , R. Y. and Tani , Y. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest(tm) in breast carcinoma by image analysis . Pathol. Int. , 51 , 3336 ( 2001 ).
  • 21
    ) Sarup , J. C. , Johnson , R. M. , King , K. L. , Fendly , B. M. , Lipari , M. T. , Napier , M. A. , Ullrich , A. and Shepard , H. M. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth . Growth Regul. , 1 , 7282 ( 1991 ).
  • 22
    ) Houchens , D. P. , Ovejera , A. A. and Barker , A. D. The therapy of human tumors in athymic (nude) mice . In “ Proc. Symp. The Use of Athymic (Nude) Mice in Cancer Research ,” ed. D. P. Houchens and A. A. Ovejera , pp. 267 ( 1978 ). Gustav Fisher , New York .
  • 23
    ) Berns , E. M. , Klijn , J. G. , van Staveren , I. L. , Portengen , H. , Noordegraaf , E. and Foekens , J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors . Eur. J. Cancer , 28 , 697700 ( 1992 ).
  • 24
    ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M. F. Studies of the HER2/neu protooncogene in human breast and ovarian cancer . Science , 244 , 707712 ( 1989 ).
  • 25
    ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H. HER2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138143 ( 1999 ).
  • 26
    ) Kern , J. A. , Schwartz , D. A. , Nordberg , J. E. , Weiner , D. B. , Greene , M. I. , Torney , L. and Robinson , R. A. P185neu expression in human lung adenocarcinomas predicts shortened survival . Cancer Res. , 50 , 51845187 ( 1990 ).
  • 27
    ) Jaehne , J. , Urmacher , C. , Thaler , H. T. , Friedlander-Klar , H. , Cordon-Cardo , C. and Meyer , H. J. Expression of Her2/neu oncogene product p185 in correlation to clinico-pathological and prognostic factors of gastric carcinoma . J. Cancer Res. Clin. Oncol. , 118 , 474479 ( 1992 ).
  • 28
    ) D'Emilia , J. , Bulovas , K. , D'Ercole , K. , Wolf , B. , Steele , G. and Summerhayes , I. C. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon . Oncogene , 4 , 12331239 ( 1989 ).
  • 29
    ) Al-Kasspooles , M. , Moore , J. H. , Orringer , M. B. and Beer , D. G. Amplification and over-expression of the ECFR and serbB-2 genes in human esophageal adenocarcinomas . Int. J. Cancer , 54 , 213219 ( 1993 ).
  • 30
    ) Neal , D. E. , Marsh , C. , Bennett , M. K. , Abel , P. D. , Hall , R. R. , Sainsbury , J. R. and Harris , A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumors . Lancet , i , 366368 ( 1985 ).
  • 31
    ) Lei , S. , Appert , H. E. , Nakata , B. , Domenico , D. R. , Kim , K. and Howard , J. M. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened surival . Int. J. Pancreatol. , 17 , 1521 ( 1995 ).
  • 32
    ) Seki , A. , Yoshinouchi , M. , Seki , N. , Kodama , J. , Miyagi , Y. and Kudo , T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer . Int. J. Oncol. , 17 , 103106 ( 2000 ).
  • 33
    ) Afify , A. M. , Werness , B. A. and Mark , H. F. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma . Exp. Mol. Pathol. , 66 , 163169 ( 1999 ).
  • 34
    ) Kim , Y. T. , Kim , J. W. and Lee , J. W. c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors . Cancer Lett. , 132 , 9197 ( 1998 ).
  • 35
    ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H. HER-2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138143 ( 1999 ).
  • 36
    ) Leitzel , K. , Teramoto , Y. , Konrad , K. , Chinchilli , V. M. , Volas , G. , Grossberg , H. , Harvey , H. , Demers , L. and Lipton , A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer . J. Clin. Oncol. , 13 , 11291135 ( 1995 ).
  • 37
    ) Berns , E. M. , Foekens , J. A. , van Staveren , I. L. , van Putten , W. L. , de Koning , H. Y. , Portengen , H. Z. and Klijn , J. G. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment . Gene , 159 , 1118 ( 1995 ).
  • 38
    ) Bianco , A. R. , de Laurentis , M. , Carlomagno , C. , Lauria , R. , Petrella , G. , Panico , L. , Pettinato , G. , Perrone , F. , Gallo , C. , Marinelli , A. and De Placido , S. 20 year update of the Naples gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy . Proc. Am. Soc. Clin. Oncol. , 17 , 97a ( 1998 ).
  • 39
    ) Yamauchi , H. , O'Neill , A. , Gelman , R. , Carney , W. , Tenney , D. Y. , Hosch , S. and Hayes , D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER2/c-neu protein . J. Clin. Oncol. , 15 , 25182525 ( 1997 ).
  • 40
    ) Pietras , R. J. , Arboleda , J. , Reese , D. M. , Wongvipat , N. , Pegram , M. D. , Ramos , L. , Gorman , C. M. , Parker , M. G. , Sliwkowski , M. X. and Slamon , D. J. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells . Oncogene , 10 , 24352446 ( 1995 ).
  • 41
    ) Benz , C. C. , Scott , G. K. , Sarup , J. C. , Johnson , R. M. , Tripathy , D. , Coronado , E. , Shepard , H. M. and Osborne , C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu . Breast Cancer Res. Treat. , 24 , 8595 ( 1992 ).
  • 42
    ) Bertram , J. , Killian , M. , Brysch , W. , Schlingensiepen , K. H. and Kneba , M. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides . Biochem. Biophys. Res. Commun. , 200 , 661667 ( 1994 ).
  • 43
    ) Cooler , R. , Lupus , R. , Backs , S. S. and Gelmann , E. P. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification . Br. J. Cancer , 70 , 819825 ( 1994 ).
  • 44
    ) Hudziak , R. M. , Lewis , G. D. , Winget , M. , Fendly , B. M. , Shepard , H. M. and Ullrich , S. A. P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor . Mol. Cell. Biol. , 9 , 11651172 ( 1989 ).
  • 45
    ) Pegram , M. D. , Lipton , A. , Hayes , D. F. , Weber , B. L. , Baselga , J. M. , Tripathy , D. , Baly , D. , Baughman , S. A. , Twaddell , T. , Glaspy , J. A. and Slamon , D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing meta-static breast cancer refractory to chemotherapy treatment . J. Clin. Oncol. , 16 , 26592671 ( 1998 ).
  • 46
    ) Baselga , J. , Norton , L. , Albanell , J. , Kim , Y. M. and Mendelsohn , J. Recombinant humanized anti-HER2 antibody (HERCEPTIN(tm)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts . Cancer Res. , 58 , 28252831 ( 1998 ).
  • 47
    ) Moasser , M. M. , Basso , A. , Averbuch , S. D. and Rosen , N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells . Cancer Res. , 61 , 71847188 ( 2001 ).
  • 48
    ) Cuello , M. , Ettenberg , S. A. , Clark , A. S. , Keane , M. M. , Posner , R. H. , Nau , M. M. , Dennis , P. A. and Lipkowitz , S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 . Cancer Res. , 61 , 48924900 ( 2001 ).